$22.61
-0.16-0.70%
Pre-Market: 4:55 AM EDT
15 minutes delayed
Comments
Loading...
Hims & Hers Health
HIMSNYSE
Unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Hims & Hers Health (NYSE:HIMS) Stock, Analyst Ratings, Price Targets, Forecasts
Hims & Hers Health Inc has a consensus price target of $16.69 based on the ratings of 17 analysts. The high is $26 issued by B of A Securities on June 13, 2024. The low is $6 issued by Piper Sandler on May 26, 2022. The 3 most-recent analyst ratings were released by Truist Securities, TD Cowen, and Piper Sandler on July 18, 2024, July 11, 2024, and July 11, 2024, respectively. With an average price target of $22 between Truist Securities, TD Cowen, and Piper Sandler, there's an implied -2.70% downside for Hims & Hers Health Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Truist Securities
TD Cowen
Piper Sandler
Jefferies
B of A Securities
1calculated from analyst ratings
Analyst Ratings for Hims & Hers Health
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/18/2024 | Buy Now | 1.72% | Truist Securities | Jailendra Singh | $13 → $23 | Maintains | Hold | Get Alert |
| 07/11/2024 | Buy Now | 10.57% | TD Cowen | Jonna Kim | $15 → $25 | Maintains | Buy | Get Alert |
| 07/11/2024 | Buy Now | -20.39% | Piper Sandler | Korinne Wolfmeyer | $16 → $18 | Maintains | Neutral | Get Alert |
| 06/27/2024 | Buy Now | 1.72% | Jefferies | Glen Santangelo | $14 → $23 | Maintains | Hold | Get Alert |
| 06/13/2024 | Buy Now | 14.99% | B of A Securities | Michael Cherny | $22 → $26 | Maintains | Buy | Get Alert |
| 06/03/2024 | Buy Now | -2.7% | B of A Securities | Michael Cherny | $17.25 → $22 | Maintains | Buy | Get Alert |
| 05/22/2024 | Buy Now | 6.15% | Canaccord Genuity | Maria Ripps | $20 → $24 | Maintains | Buy | Get Alert |
| 05/22/2024 | Buy Now | -11.54% | Citigroup | Daniel Grosslight | $16 → $20 | Downgrade | Buy → Neutral | Get Alert |
| 05/07/2024 | Buy Now | -29.23% | Deutsche Bank | George Hill | $14 → $16 | Maintains | Hold | Get Alert |
| 05/07/2024 | Buy Now | -42.5% | Piper Sandler | Korinne Wolfmeyer | $11 → $13 | Maintains | Neutral | Get Alert |
| 04/16/2024 | Buy Now | -33.66% | Jefferies | Glen Santangelo | $17 → $15 | Downgrade | Buy → Hold | Get Alert |
| 04/10/2024 | Buy Now | -11.54% | Canaccord Genuity | Maria Ripps | → $20 | Initiates | → Buy | Get Alert |
| 02/27/2024 | Buy Now | -24.81% | Guggenheim | Jack Wallace | $15 → $17 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | -29.23% | Citigroup | Daniel Grosslight | $12 → $16 | Maintains | Buy | Get Alert |
| 02/27/2024 | Buy Now | -51.35% | Piper Sandler | Michael Lavery | $9 → $11 | Maintains | Neutral | Get Alert |
| 02/27/2024 | Buy Now | -42.5% | Truist Securities | Jailendra Singh | $10 → $13 | Maintains | Hold | Get Alert |
| 02/26/2024 | Buy Now | -55.77% | Leerink Partners | Michael Cherny | → $10 | Initiates | → Market Perform | Get Alert |
| 01/05/2024 | Buy Now | -33.66% | Tigress Financial | Ivan Feinseth | $14 → $15 | Maintains | Buy | Get Alert |
| 08/09/2023 | Buy Now | -55.77% | Truist Securities | Jailendra Singh | $12 → $10 | Maintains | Hold | Get Alert |
| 08/08/2023 | Buy Now | -38.08% | Credit Suisse | Jonathan Yong | → $14 | Reiterates | Outperform → Outperform | Get Alert |
| 07/28/2023 | Buy Now | -51.35% | TD Cowen | Jonna Kim | → $11 | Initiates | → Outperform | Get Alert |
| 06/15/2023 | Buy Now | -38.08% | Tigress Financial | Ivan Feinseth | $12 → $14 | Reiterates | → Buy | Get Alert |
| 05/30/2023 | Buy Now | -51.35% | Piper Sandler | Michael Lavery | $12 → $11 | Maintains | Neutral | Get Alert |
| 05/09/2023 | Buy Now | -33.66% | B of A Securities | Michael Cherny | $13.5 → $15 | Maintains | Buy | Get Alert |
| 05/09/2023 | Buy Now | -46.93% | Piper Sandler | Michael Lavery | $11 → $12 | Maintains | Neutral | Get Alert |
| 04/27/2023 | Buy Now | -20.39% | Guggenheim | Jack Wallace | $15 → $18 | Maintains | Buy | Get Alert |
| 04/26/2023 | Buy Now | -51.35% | Piper Sandler | Korinne Wolfmeyer | $10 → $11 | Maintains | Neutral | Get Alert |
| 04/11/2023 | Buy Now | -55.77% | Baird | Vikram Kesavabhotla | → $10 | Initiates | → Neutral | Get Alert |
| 03/01/2023 | Buy Now | -38.08% | Credit Suisse | Jonathan Yong | $8 → $14 | Maintains | Outperform | Get Alert |
| 02/28/2023 | Buy Now | -33.66% | Guggenheim | Jack Wallace | → $15 | Reiterates | → Buy | Get Alert |
| 02/28/2023 | Buy Now | -46.93% | Truist Securities | Jailendra Singh | $7 → $12 | Maintains | Hold | Get Alert |
| 02/28/2023 | Buy Now | -38.08% | Citigroup | Daniel Grosslight | $9 → $14 | Maintains | Buy | Get Alert |
| 02/28/2023 | Buy Now | -55.77% | Piper Sandler | Korinne Wolfmeyer | $7 → $10 | Maintains | Neutral | Get Alert |
| 02/28/2023 | Buy Now | -40.29% | B of A Securities | Michael Cherny | $11.5 → $13.5 | Maintains | Buy | Get Alert |
| 02/09/2023 | Buy Now | -51.35% | Jefferies | Glen Santangelo | $7 → $11 | Upgrade | Hold → Buy | Get Alert |
| 01/12/2023 | Buy Now | -46.93% | Tigress Financial | Ivan Feinseth | $11 → $12 | Maintains | Buy | Get Alert |
| 11/08/2022 | Buy Now | -62.41% | B of A Securities | Michael Cherny | $7.5 → $8.5 | Upgrade | Neutral → Buy | Get Alert |
| 11/08/2022 | Buy Now | — | SVB Leerink | Joy Zhang | — | Upgrade | Underperform → Market Perform | Get Alert |
| 10/17/2022 | Buy Now | -73.46% | Piper Sandler | Korinne Wolfmeyer | $8 → $6 | Downgrade | Overweight → Neutral | Get Alert |
| 09/07/2022 | Buy Now | -69.04% | Truist Securities | Jailendra Singh | → $7 | Initiates | → Hold | Get Alert |
| 08/10/2022 | Buy Now | -64.62% | Credit Suisse | Jonathan Yong | $7 → $8 | Maintains | Outperform | Get Alert |
| 08/09/2022 | Buy Now | -77.89% | SVB Leerink | Joy Zhang | $4 → $5 | Maintains | Underperform | Get Alert |
| 07/15/2022 | Buy Now | -82.31% | SVB Leerink | Joy Zhang | → $4 | Initiates | → Underperform | Get Alert |
| 05/26/2022 | Buy Now | -73.46% | Piper Sandler | Sean Wieland | $8 → $6 | Maintains | Overweight | Get Alert |
| 05/10/2022 | Buy Now | -73.46% | Citigroup | Daniel Grosslight | $9 → $6 | Maintains | Buy | Get Alert |
| 04/14/2022 | Buy Now | -55.77% | Guggenheim | Jack Wallace | → $10 | Initiates | → Buy | Get Alert |
| 03/10/2022 | Buy Now | -69.04% | Deutsche Bank | George Hill | → $7 | Initiates | → Hold | Get Alert |
| 12/20/2021 | Buy Now | -60.19% | Citigroup | — | — | Maintains | Buy | Get Alert |
| 12/02/2021 | Buy Now | -69.04% | Jefferies | Glen Santangelo | — | Initiates | → Hold | Get Alert |
| 11/11/2021 | Buy Now | -46.93% | Piper Sandler | Sean Wieland | — | Upgrade | Neutral → Overweight | Get Alert |
FAQ
What is the target price for Hims & Hers Health (HIMS) stock?
The latest price target for Hims & Hers Health (NYSE:HIMS) was reported by Truist Securities on July 18, 2024. The analyst firm set a price target for $23.00 expecting HIMS to rise to within 12 months (a possible 1.72% upside). 21 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Hims & Hers Health (HIMS)?
The latest analyst rating for Hims & Hers Health (NYSE:HIMS) was provided by Truist Securities, and Hims & Hers Health maintained their hold rating.
When was the last upgrade for Hims & Hers Health (HIMS)?
The last upgrade for Hims & Hers Health Inc happened on February 9, 2023 when Jefferies raised their price target to $11. Jefferies previously had a hold for Hims & Hers Health Inc.
When was the last downgrade for Hims & Hers Health (HIMS)?
The last downgrade for Hims & Hers Health Inc happened on May 22, 2024 when Citigroup changed their price target from $16 to $20 for Hims & Hers Health Inc.
When is the next analyst rating going to be posted or updated for Hims & Hers Health (HIMS)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Hims & Hers Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Hims & Hers Health was filed on July 18, 2024 so you should expect the next rating to be made available sometime around July 18, 2025.
Is the Analyst Rating Hims & Hers Health (HIMS) correct?
While ratings are subjective and will change, the latest Hims & Hers Health (HIMS) rating was a maintained with a price target of $13.00 to $23.00. The current price Hims & Hers Health (HIMS) is trading at is $22.61, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.